Erlotinib-Conjugated Iron Oxide Nanoparticles as a Smart Cancer-Targeted Theranostic Probe for MRI

NCU Institutional Repository > 生醫理工學院 > 生命科學系 > 期刊論文 > Item 987654321/102542

請使用永久網址來引用或連結此文件: https://ir.lib.ncu.edu.tw/handle/987654321/102542

題名:	Erlotinib-Conjugated Iron Oxide Nanoparticles as a Smart Cancer-Targeted Theranostic Probe for MRI
作者:	許斐婷;Ali, Ahmed Atef Ahmed;Hsu, Fei-Ting;Hsieh, Chia-Ling;Shiau, Chia-Yang;Chiang, Chiao-Hsi;Wei, Zung-Hang;Chen, Cheng-Yu;Huang, Hsu-Shan
貢獻者:	生醫理工學院生命科學系
關鍵詞:	13/95;14/1;14/19;14/28;14/34;59/57;631/154/152;631/154/433;631/67/1059/602;631/67/2321;639/301/54/152;64/60;82/80;96/63;Animals;Cancer;Contrast Media - chemistry;Contrast Media - pharmacology;Drug Delivery Systems - methods;Erlotinib Hydrochloride - chemistry;Erlotinib Hydrochloride - pharmacology;Humanities and Social Sciences;Humans;Inhibitor drugs;Iron oxides;Jurkat Cells;Magnetic Resonance Imaging;Magnetite Nanoparticles - chemistry;Magnetite Nanoparticles - therapeutic use;Magnetite Nanoparticles - ultrastructure;Male;Mice, Inbred BALB C;Mice, Nude;multidisciplinary;Nanoparticles;Neoplasms, Experimental - diagnostic imaging;Neoplasms, Experimental - metabolism;Science;Targeted cancer therapy;Tumors;Xenografts
日期:	2016-11-11
上傳時間:	2026-04-23 11:12:36 (UTC+8)
出版者:	Nature Publishing Group;London: Nature Publishing Group UK
摘要:	摘要： We designed and synthesized novel theranostic nanoparticles that showed the considerable potential for clinical use in targeted therapy, and non-invasive real-time monitoring of tumors by MRI. Our nanoparticles were ultra-small with superparamagnetic iron oxide cores, conjugated to erlotinib (FeDC-E NPs). Such smart targeted nanoparticles have the preference to release the drug intracellularly rather than into the bloodstream, and specifically recognize and kill cancer cells that overexpress EGFR while being non-toxic to EGFR-negative cells. MRI, transmission electron microscopy and Prussian blue staining results indicated that cellular uptake and intracellular accumulation of FeDC-E NPs in the EGFR overexpressing cells was significantly higher than those of the non-erlotinib-conjugated nanoparticles. FeDC-E NPs inhibited the EGFR–ERK–NF-κB signaling pathways, and subsequently suppressed the migration and invasion capabilities of the highly invasive and migrative CL1-5-F4 cancer cells. In vivo tumor xenograft experiments using BALB/c nude mice showed that FeDC-E NPs could effectively inhibit the growth of tumors. T 2 -weighted MRI images of the mice showed significant decrease in the normalized signal within the tumor post-treatment with FeDC-E NPs compared to the non-targeted control iron oxide nanoparticles. This is the first study to use erlotinib as a small-molecule targeting agent for nanoparticles. 其他題名： Sci Rep 出版者： London: Nature Publishing Group UK 出版日期： 2016-11-11 出處： Scientific reports, 2016-11, Vol.6 (1), p.36650, Article 36650 資源來源： Springer Nature Link Open Access Journals 版權： The Author(s) 2016 版權： Copyright Nature Publishing Group Nov 2016 版權： Copyright © 2016, The Author(s) 2016 The Author(s) 識別號： ISSN: 2045-2322 識別號： EISSN: 2045-2322 識別號： DOI: 10.1038/srep36650 識別號： PMID: 27833124
顯示於類別:	[生命科學系] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	16	檢視/開啟

在NCUIR中所有的資料項目都受到原著作權保護.

社群 sharing

資料載入中.....